First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
It offers quick relief in various types of Coughs, Colds and Sore Throat,
The Group will continue to make proactive investments of its management resources in the life science business
Revenue is up 23% whereas Profit After Tax expands 29% for the company
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
The training center will focus on providing radiation oncologists, radiotherapy technologists, and medical physicists with the necessary skills
Subscribe To Our Newsletter & Stay Updated
